Endorsed by the EULAR, SCMR & EACVI
CardioRheumatology Course, This program was in August 2023, The program of 2025 will be published in Spring 2025
|
08:00 – 08:30 |
Registration |
|
|
08:30 |
Welcome |
|
|
R. Nijveldt, Nijmegen (NL) – M. Nurmohamed, Amsterdam (NL) |
||
|
08:40 |
SESSION 1: Cardiovascular and autoimmune disease |
|
|
M. Nurmohamed, Amsterdam (NL) – S. Mavrogeni, Athens (GR) |
||
|
08:40 |
Inflammation and Cardiovascular disease in Rheumatoid Arthritis |
|
|
M. Nurmohamed, Amsterdam (NL) |
||
|
09:20 |
Cardiovascular disease in Systemic Lupus Erythematodes |
|
|
S. van Leuven, Nijmegen (NL) |
||
|
09:45 |
Cardiovascular disease in Systemic Vasculitis |
|
|
T. Dimitroulas, Thessaloniki (GR) |
||
|
10:15 – 10:45 |
COFFEE BREAK |
|
|
10:45 |
SESSION 2: Markers of cardiovascular inflammation |
|
|
R. Nijveldt, Nijmegen (NL) – A. Pepe, Pisa (IT) |
||
|
10:45 |
Cardiovascular Risk Management in Rheumatic patients |
|
|
C. Popa, Nijmegen (NL) |
||
|
11:10 |
Advanced echocardiography for inflammatory heart disease |
|
|
N. Ajmone, Leiden (NL) |
||
|
11:35 |
The role of CMR in inflammatory cardiovascular disease |
|
|
V. Puntmann, Frankfurt (DE) |
||
|
12:00 |
From exclusive biomarker to multimodality assessment |
|
|
M. Buch, Manchester (UK) |
||
|
12:25 – 13:15 |
LUNCH |
|
|
13:15 |
SESSION 3: Extent and progression in cardiovascular involvement |
|
|
C. Bucciarelli-Ducci, Bristol (UK) – R. Nijveldt, Nijmegen (NL) |
||
|
13:15 |
The role of the innate immune system in atherosclerosis |
|
|
N. Riksen, Nijmegen (NL) |
||
|
13:40 |
Importance of early detection and treatment of inflammation in autoimmune diseases |
|
|
P. van Riel, Nijmegen (NL) |
||
|
14:05 |
PET/CT detection of disease extent and progression |
|
|
A Gimelli, Pisa (IT) |
||
|
14:30 – 14:45 |
TEA BREAK |
|
|
14:45 |
SESSION 4: Cardiac prognosis in autoimmune disease |
|
|
N. Ntusi, Cape Town (South Africa) |
||
|
14:45 |
Amyloid and recurrent pericarditis in autoimmune disease |
|
|
H. Lachmann (UK) |
||
|
15:05 |
Antiphospholipid syndrome in autoimmune disease |
|
|
C. Bratis, Manchester (UK) |
||
|
15:25 |
Pulmonary hypertension in Systemic Sclerosis |
|
|
M. Vonk, Nijmegen (NL) |
||
|
15:45 |
The influence of multimodality imaging on treatment |
|
|
S. Mavrogeni, Athens (GR) |
||
|
16:10 – 16:30 |
SOFT DRINK BREAK |
|
|
16:30 |
SESSION 5: Multimodality assessment in clinical practice |
|
|
L. Gargani, Pisa (IT)– A. Gimelli, Pisa (IT) |
||
|
16:30 |
Subclinical myocardial inflammation in Systemic Sclerosis |
|
|
N. Ntusi, Cape Town (South Africa) |
||
|
16:50 |
Cardiovascular involvement in Ankylosing Spondylitis |
|
|
S. Biesbroek, Amsterdam (NL) |
||
|
17:10 |
Cardiovascular assessment in Rheumatic disease |
|
|
L. Robbers, Amsterdam (NL) |
||
|
17:30 |
Myocardial side effects of anti-rheumatic drugs |
|
|
S. El Messaoudi, Nijmegen (NL) |
||
|
17:50 |
Closing remarks |
|
|
R. Nijveldt, Nijmegen (NL) – S. Mavrogeni, Athens (GR) |
||
